Document Detail

Increased mitotic rate coincident with transient telomere lengthening resulting from pim-1 overexpression in cardiac progenitor cells.
Jump to Full Text
MedLine Citation:
PMID:  22915504     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiac regeneration following myocardial infarction rests with the potential of c-kit+ cardiac progenitor cells (CPCs) to repopulate damaged myocardium. The ability of CPCs to reconstitute the heart is restricted by patient age and disease progression. Increasing CPC proliferation, telomere length, and survival will improve the ability of autologous CPCs to be successful in myocardial regeneration. Prior studies have demonstrated enhancement of myocardial regeneration by engineering CPCs to express Pim-1 kinase, but cellular and molecular mechanisms for Pim-1-mediated effects on CPCs remain obscure. We find CPCs rapidly expand following overexpression of cardioprotective kinase Pim-1 (CPCeP), however, increases in mitotic rate are short-lived as late passage CPCePs proliferate similar to control CPCs. Telomere elongation consistent with a young phenotype is observed following Pim-1 modification of CPCeP; in addition, telomere elongation coincides with increased telomerase expression and activity. Interestingly, telomere length and telomerase activity normalize after several rounds of passaging, consistent with the ability of Pim-1 to transiently increase mitosis without resultant oncogenic transformation. Accelerating mitosis in CPCeP without immortalization represents a novel strategy to expand the CPC population in order to improve their therapeutic efficacy.
Authors:
Christopher T Cottage; Lauren Neidig; Balaji Sundararaman; Shabana Din; Anya Y Joyo; Brandi Bailey; Natalie Gude; Nirmala Hariharan; Mark A Sussman
Related Documents :
10562264 - Altered complexity and correlation properties of r-r interval dynamics before the spont...
12643434 - Atrial fibrillation: current surgical options and their assessment.
15505084 - Radiation exposure during catheter ablation of atrial fibrillation.
15823624 - Antithrombotic strategies for the management of non-valvular atrial fibrillation.
15834444 - Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone c...
2109924 - Effects of glyburide on ischemia-induced changes in extracellular potassium and local m...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Stem cells (Dayton, Ohio)     Volume:  30     ISSN:  1549-4918     ISO Abbreviation:  Stem Cells     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-23     Completed Date:  2013-03-22     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  9304532     Medline TA:  Stem Cells     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2512-22     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 AlphaMed Press.
Affiliation:
San Diego State Heart Institute, San Diego State University, San Diego, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiotoxins / pharmacology
Cell Proliferation
Cell Survival
Cells, Cultured
Doxorubicin / pharmacology
Enzyme Activation
Gene Expression
Green Fluorescent Proteins / biosynthesis,  genetics
Mice
Mitosis*
Myocardium / cytology*
Phosphorylation
Protein Binding
Protein Interaction Mapping
Protein Processing, Post-Translational
Proto-Oncogene Proteins c-myc / antagonists & inhibitors,  metabolism
Proto-Oncogene Proteins c-pim-1 / genetics,  metabolism*
Regenerative Medicine
Stem Cells / enzymology,  metabolism,  physiology*
Telomerase / metabolism
Telomere Homeostasis* / drug effects
Thiazoles / pharmacology
Grant Support
ID/Acronym/Agency:
P01 HL085577/HL/NHLBI NIH HHS; R01 HL067245/HL/NHLBI NIH HHS; R01 HL105759/HL/NHLBI NIH HHS; R01 HL113656/HL/NHLBI NIH HHS; R21 HL102613/HL/NHLBI NIH HHS; R21 HL102714/HL/NHLBI NIH HHS; R21 HL104544/HL/NHLBI NIH HHS; R37 HL091102/HL/NHLBI NIH HHS; RC1 HL100891/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 0/Cardiotoxins; 0/Myc protein, mouse; 0/Proto-Oncogene Proteins c-myc; 0/Thiazoles; 0/enhanced green fluorescent protein; 147336-22-9/Green Fluorescent Proteins; 23214-92-8/Doxorubicin; EC 2.7.11.1/Pim1 protein, mouse; EC 2.7.11.1/Proto-Oncogene Proteins c-pim-1; EC 2.7.7.49/Telomerase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Stem Cells
Journal ID (iso-abbrev): Stem Cells
Journal ID (publisher-id): stem
ISSN: 1066-5099
ISSN: 1549-4918
Publisher: Wiley Subscription Services, Inc., A Wiley Company, Hoboken
Article Information
Download PDF
Copyright © 2012 AlphaMed Press
open-access:
Received Day: 07 Month: 6 Year: 2012
Accepted Day: 23 Month: 7 Year: 2012
Print publication date: Month: 11 Year: 2012
Electronic publication date: Day: 22 Month: 8 Year: 2012
Volume: 30 Issue: 11
First Page: 2512 Last Page: 2522
PubMed Id: 22915504
ID: 3479348
DOI: 10.1002/stem.1211

Increased Mitotic Rate Coincident with Transient Telomere Lengthening Resulting from Pim-1 Overexpression in Cardiac Progenitor Cells
Christopher T Cottage
Lauren Neidig
Balaji Sundararaman
Shabana Din
Anya Y Joyo
Brandi Bailey
Natalie Gude
Nirmala Hariharan
Mark A Sussman
San Diego State Heart Institute, San Diego State UniversitySan Diego, California, USA
Correspondence: Mark A. Sussman, Ph.D., San Diego State Heart Institute, San Diego State University, 5500 Campanile Drive, San Diego, California, USA. Telephone: 92-182 619-594-42983; Fax: 92-619-594-5635;; e-mail: sussman@heart.sdsu.edu
Author contributions: C.T.C.: conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing, L.N., B.S., S.D., A.J., B.B., N.G., and N.H.: collection and/or assembly of data, M.S.: conception and design, financial support, manuscript writing, and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.

INTRODUCTION

Regenerative medicine to combat the devastating loss of myocardial contractility resulting from myocardial infarction (MI) has demonstrated promising initial results [1]. Increased left ventricular ejection fraction, decreased infarct size, and increased hemodynamic function following adoptive transfer of autologous c-kit+ cardiac progenitor cells (CPCs) suggests that infusion of CPCs play a pivotal role in cardiac regeneration [13]. However, CPCs isolated from patients are heterogeneous in nature and suffer from consequential impairment rooted in the underlying cardiomyopathic disease of the donor. Specifically, MI survivors typically are elderly, suffer from chronic cardiomyopathies or diabetes and thus possess CPCs with compromised regenerative potential [4, 5]. Aged CPCs exhibit short telomeres, inactive telomerase (TERT), and impaired proliferation, thereby limiting replicative capacity and generation of the population required for effective cellular cardiomyogenic treatment. Strategies aimed at accelerating proliferation and extending replicative lifespan of CPCs will be essential to overcome inherent limitations of harvested patient CPC populations derived from weak, aged, or damaged myocardium.

Telomeres are a nucleoprotein complex at the ends of linear chromosomes consisting of several kilobases of 5′-TTAGGG-3′ DNA repeats and telomere associated proteins collectively known as the shelterin complex [6, 7]. Shelterin assembles tightly on the telomere to prevent chromosomal instability and inhibit DNA damage machinery [8, 9]. Repeated rounds of mitosis or endogenous oxidative stress successively diminishes telomeric repeats resulting in critically short telomeres [10]. Short telomeres can lead to chromosomal fusions, cellular senescence, apoptosis, or transformation [1113]. Telomere homeostasis is maintained by TERT, the reverse transcriptase responsible for telomere elongation [14], together with an associated RNA component (Terc) [15]. TERT adds telomeric repeats after DNA replication has taken place [16, 17], but TERT activation can also be initiated at transcriptional and post-translational levels [18]. Serine/threonine kinases Akt and PKC positively regulate TERT, activating enzyme activity and increasing telomere length [19]. c-Myc, a transcription factor that regulates as many as 15% of all known human genes [14] also promotes TERT transcription leading to increased TERT protein levels and activity [14, 20].

Pim-1, a serine/threonine kinase, promotes cell proliferation and survival in conjunction with c-Myc [2123]. Previous studies from our group demonstrated enhanced myocardial regeneration by genetically engineering CPCs to overexpress Pim-1 [2] but the underlying cellular and molecular basis of Pim-1-mediated effects upon CPCs remain obscure. Understanding the molecular basis for Pim-1 enhancement of CPC activity is essential to delineate the mechanistic basis of Pim-1 activity and determine the potential of Pim-1-modified CPCs for incorporation into protocols for augmented clinical treatment of heart failure. Findings presented in this study demonstrate telomere length is transiently increased in CPCs overexpressing Pim-1 (CPCeP) correlated to acceleration of mitotic rate and decreased cell cycle time. Telomeric lengthening and telomerase activity stimulated by Pim-1 is dependent upon c-Myc activation and protects CPCs from doxorubicin-induced telomere attrition. Revealing these underlying mechanisms of telomere preservation and acceleration of mitosis by Pim-1 offers exciting new potential therapeutic interventions for CPC-mediated cardiac regeneration in heart failure.


MATERIALS AND METHODS
CPC Isolation, Culture, and Transduction

CPCs were isolated from mouse hearts based on expression of c-kit as previously described [24, 25]. CPCs from friend leukemia virus B inbred strain (FVB) mouse hearts at passage 14 were plated (0.5 × 104 cells per well) in six-well plates, transduced with lentivirus (multiplicity of infection = 10), expanded, and isolated by fluorescently activated cell sorting to enrich for GFP+ cells. Cells were then maintained and passaged in CPC media [24]. Passage numbers indicated throughout are passage number post-transduction.

Telomere Length Measurements

Telomere length was analyzed by quantitative fluorescent in situ hybridization (Q-FISH) and confocal microscopy. PNA probe was purchased from DAKO (K5325, Glostrup, Denmark, http://www.dako.com) and used according to manufacturer's protocol on cells fixed with 3:1 methanol/ acetic acid fixative and dried on glass chamber slides. Telomere signal was acquired in each nucleus using Leica LCS confocal software. To control for interday variation, slides with defined amounts of fluorescence were utilized to acquire appropriate signal intensity. A minimum of 150 CPCs per group was analyzed.

Telomeric Repeat Amplification Protocol (TRAP)

For whole cell TRAP assays, CPC plates were scraped in 3-[3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonate buffer and then centrifuged at 4°C. Protein concentration was determined using Bradford assay and then manufacturer's protocol was followed for reverse transcriptase polymerase chain reaction (S7701, Millipore, Billerica, MA, http://www.millipore.com). Each group was subjected to heat inactivation as negative control. TSR8 positive controls with known TERT activity were used to create standard curve and assign TRAP activity units. Results are averages of three independent experiments in triplicate ± SEM.

Proximity Ligation Assay (PLA)

The PLA kit was purchased from Olink Biosciences, and the manufacturer protocol was followed (Uppsala, Sweden, http://www.olink.com). Briefly, primary antibodies were applied after an hour block in 10% horse serum and incubated overnight at 4°C. The following day the slides were washed, then plus and minus PLA probes were applied in blocking buffer and incubated at 37°C. Next the slides were treated with ligation solution for 30 minutes followed by 90 minutes of amplification solution all at 37°C. After three washes, slides were treated with Sytox Blue and coverslipped in Vecta-shield mounting medium.

CyQUANT Assay

A total of 1,000 CPCs were plated and allowed to adhere to a 96-well dish. CyQUANT solution was added at indicated time points and measured according to manufacturer's protocol (Invitrogen, Carlsbad, CA, http://www.invitrogen.com, Catalog number C35006). A CyQUANT assay performed 4 hours after plating confirms equal adherence of CPCs regardless of Pim-1 modification (supporting information Fig. 1A).

Statistical Analysis

All data are expressed as mean ± SEM. Statistical analysis was performed using Student's t test and ANOVA with Tukey's post hoc analysis as appropriate. Telomere length distribution significance was determined using Kolmogorov-Smirnov test. p values less than 0.05 are considered significant.


RESULTS
Mitotic Rate Increased by Pim-1 Expression in CPCeP

Population proliferation in CPCeP early after transduction and subsequent passaging is increased 1.37-fold relative to that of control eGFP-expressing CPCs (CPCe) measured by CyQUANT DNA content assay. However, population proliferation rates of CPCePs equal that of CPCe by 18 passages postinfection (Fig. 1A). Increases in proliferation correlates to a significantly shorter doubling time in early passage CPCeP relative to CPCe (29.4 hours vs. 36.3 hours), but doubling time normalizes with CPCe at later passages (Fig. 1B). Pim-1 levels remain high throughout early and late passages (supporting information Fig. 2A) indicating that observed slowing of cell proliferation in late passage does not stem from diminished Pim-1 level.

Population doubling time is significantly increased 33% in CPCs isolated from hearts of 13-month-old mice (OCPC) relative to CPCs from 2-month old hearts (p = .02, Fig. 1C). Ability of Pim-1 expression to accelerate the mitotic clock in CPCs from aged hearts was assessed using old CPCs overexpressing Pim-1 (OCPCeP). Similar to findings with CPCeP, increased cellular proliferation of OCPCeP is evident relative to comparably prepared old eGFP-expressing CPC (OCPCe) controls measured by CyQUANT (supporting information Fig. 1; 11% and 29% increases at days 3 and 5, respectively). Enhanced OCPCeP proliferation that correlates with population doubling time significantly decreased by 15% compared to OCPCe (Fig. 1C). Rate of cell cycling for CPCs is not increased by overexpression of Pim-1 dominant negative (CPCePDN) mutant that lacks kinase activity, indicating that kinase activity is necessary for decreased doubling time. The increased mitotic rate of CPCeP is comparable to that observed with CPCs engineered to overexpress TERT, suggesting potential connection between Pim-1 overexpression and enhancement of TERT activity (Fig. 1C).

Telomere Elongation in CPCs with Short Telomeres

TERT activity regulates CPC growth and telomere length [26], so telomere length was compared between OCPCe and OCPCeP by QFISH. For example, OCPCe have an average telomere length of 25.8 relative fluorescent units (RFUs, Fig. 2A). Average RFUs of telomeres from OCPCeP are 2.9-fold higher than those of OCPCe indicative of telomere extension by Pim-1 kinase expression (Fig. 2A, 2B). In comparison, the average RFUs for CPCe versus OCPCe is 1.78 higher, confirming relatively shorter telomere length in OCPCe (Fig. 2C). Telomeric shortening is antagonized in aged mice by TERT overexpression [27], and increased levels of TERT gene, TERT protein, and TERT activity are observed in OCPCeP relative to OCPCe (Fig. 2D–2F, supporting information Fig. 2), providing a molecular basis for the effect of Pim-1 upon telomere length.

Acute Telomere Lengthening in CPCeP Normalizes Through Culture Passages

Increases in mitotic rate (Fig. 1) and telomere length (Fig. 2) are evident soon after Pim-1 overexpression in cultured CPCs, so persistence of these enhancements was subsequently determined by serial passaging of CPCeP versus CPCe in culture.comparative telomere measurements based upon RFUs show a significant increase of 2.1-fold for CPCeP versus CPCe from passages 4-6 (Fig. 3A, 3F; p < .01) demonstrating that Pim-1 can increase telomere length even in CPCs derived from hearts of young mice. However, the increased RFUs detected for CPCeP telomere length is lost with continued serial passage, with comparable signal between CPCeP and CPCe by passages 11-12 in culture (Fig. 3C, 3D). Participation of Pim-1 in preservation of telomere length is evident in CPCePDN that show significant 23% loss of RFUs at early passages (p < .01, Fig. 3E). Telomere extension depends upon TERT activity since CPCeP treated with TERT inhibitor MST 312 show no increase in RFUs compared to CPCe (supporting information Fig. 3). Collectively, these results establish Pim-1 as a mediator of TERT activity that can promote transient telomere elongation early after cell modification that correlates temporally with increased mitotic activity.

Telomere Extension in CPCeP Depends Upon Increased TERT Activity

Telomere average length determined by RFUs from serial passage of CPCeP shows early augmentation at passages 4-6 that subsequently normalizes to that of CPCe by passages 11-12 and is maintained comparably between CPCeP and CPCe until passages 20-22, which is considered late passage (Fig. 4A). Whereas the acute telomere lengthening in early passage CPCs correlates with significant increases in TERT activity (2.99-fold), this elevation of TERT is not present in CPCe, CPCePDN, or mid to late passage CPCeP (Fig. 4D; supporting information Fig. 2A). Specifically, TERT protein levels decrease 5.54-fold in CPCeP at passages 11-12 relative to early passage coincident with telomere length normalization. Again, TERT activity is augmented by Pim-1 kinase as demonstrated by significant reductions resulting from knockdown using short hairpin lentivirus for Pim-1 in both CPCe and CPCeP (Fig. 4D). Tumor suppressor protein p53 levels are minimal and comparable to CPCe in early passages. However, p53 precipitously increases in CPCeP through serial passaging (42.6% more in p11-12 and 21.1% more in p20-22 vs. p11-12, Fig. 4E; supporting information Fig. 2C) consistent with decreases in telomere length and TERT activity in later passages. Taken together the data suggest that TERT is upregulated early in CPCeP leading to increased TERT activity and longer telomeres. This effect reverses with serial passaging resulting in increased p53, reduced TERT, a slower rate of mitosis, and diminished telomeres (Fig. 4F).

TERT Interacts with Pim-1

Pim-1 and TERT interact directly as assessed by coimmunoprecipitation of whole cell lysates at passage 7 (supporting information Fig. 4A, 4B). Interaction is independent of kinase activity as TERT was also pulled down by immunoprecipitation with CPCePDN (supporting information Fig. 4A, 4B). Localization of Pim-1/TERT interactions was determined by proximity ligation assays (PLAs) performed using CPCe or CPCeP. TERT and Pim-1 interaction is evident in all three cell types, with the highest level of interaction evident in CPCeP (supporting information Fig. 4A, red dots). Pim-1/TERT PLA signal is absent in control CPCeP samples lacking primary antibody as well as dramatically reduced by Pim-1 kinase inhibitor Quercetagetin (Q) or silencing RNA specific to Pim-1 (siPim-1; supporting information Fig. 4C–4H). TERT phosphorylation could occur on several possible serine and threonine residues by Pim-1 [28, 29], but specific residues for pSer-TERT or pThr-TERT have not been identified. Demonstration of pSer-TERT or pThr-TERT using antibodies to TERT and phospho-threonine or phospho-serine by PLA signal shows abundant pThr-TERT signal in CPCe, CPCeP, and CPCePDN (Fig. 5A–5D) with PLA signal for pThr-TERT in CPCeP diminishing by passage 11 (Fig. 5B, 5C). Similarly, pSer-TERT PLA signal is observed throughout the cell, but diminished pSer-TERT PLA signal in CPCePDN suggests Pim-1-mediated serine phosphorylation. PLA results for pSer-TERT or pThr-TERT were corroborated by diminution of signal upon introduction of pharmacologic inhibition using Q or silencing using siPim-1 (supporting information Fig. 4D, 4G). Collectively, decreased telomere length, diminished TERT activity, together with reduced PLA signal for Pim-1/TERT and pSer/TERT in CPCePDN point to Pim-1/TERT interaction with serine residue phosphorylation augmenting TERT activation and telomere elongation.

c-Myc Inhibition Blocks Pim-1 Telomere Preservation

Synergistic interaction between c-Myc and Pim-1 that promotes CPC proliferation and survival [21, 22] implicates a role for c-Myc in the molecular mechanism of Pim-1 action. Indeed, c-Myc expression is increased 4.4-fold in early passages 4-7 CPCeP (Fig. 6A). c-Myc inhibition with the small molecule 10058-F4 (MycI, 50 μM) results in significant depression for mRNA levels of TERT the c-Myc target eLF4 in low passage CPCe and CPCeP (Fig. 6B). TERT activity activated by c-Myc [30] is significantly decreased by MycI, with greater reduction evident in CPCeP relative to CPCe (Fig. 6C, 4.52-fold decrease). Continued presence of MycI leads to significant telomere length diminution in CPCeP relative to vehicle-treated controls, with similar effects also present in CPCe (Fig. 6G, 6F) indicating a pivotal role for c-Myc in Pim-1-induced telomere maintenance.

Telomere Length Preservation After Doxorubicin

Doxorubicin (Dox), a cardiotoxic anthracycline, depletes CPCs in the myocardium through oxidative stress [31], and oxidative stress mediated by Dox leads to telomeric shortening [32]. Therefore, ability of Pim-1 to antagonize Dox-induced telomeric shortening in CPC was tested at passages 13-15 when telomere length is comparable between CPCe and CPCeP. TERT expression increases in response to Dox exposure, but challenged CPCeP exhibit increases of 1.70-fold in TERT protein and 1.28-fold in activity relative to comparably treated CPCe (Fig. 7A, 7B; p < .05). Telomere length is maintained following Dox challenge in CPCeP, whereas telomere attrition is observed in CPCe (Fig. 7D–7G). Similar to previous findings (Fig. 6), telomere preservation in Dox-challenged CPCeP depends upon c-Myc activity, as introduction of MycI abrogates telomere length preservation in CPCeP (Fig. 7H, 7I). Dox-induced apoptosis was increased 2.98-fold in CPCe relative to vehicle-treated controls measured by caspase 8 activity. In contrast, Dox failed to increase caspase 8 activity in CPCeP relative to vehicle-treated control cells (Fig. 7C). DNA synthesis as measured by bromodeoxyuridine (BrdU) incorporation is comparable over the 4-hour treatment period in either CPCe or CPCeP. Increased BrdU incorporation likely due to increased DNA damage [32, 33] as a result of Dox challenge is observed in both CPCe and CPCeP (supporting information Fig. 5B). Collectively, these results demonstrate the ability of Pim-1 to resist the detrimental effects of doxorubicin treatment on CPCs.


DISCUSSION

Current excitement related to clinical implementation of regenerative medicine is tempered by limitations in efficiency of stem cell-mediated repair, including low efficiency engraftment, persistence, and expansion of adoptively transferred cell populations. A clinical trial infusing autologous CPCs in patients suffering from MI damage with ejection fraction <40% shows partial recovery of myocardial structure and function, but the fate of donated cells cannot be readily assessed [1]. Furthermore, patient age and disease progression are likely to compromise proliferative potential and survival of CPCs in the setting of regenerative therapy. Thus strategies aimed at extending cellular replicative lifespan may be essential to reinvigorate CPCs derived from aged or chronically stressed cardiac tissue samples to reconstitute the damaged myocardium. Extrapolating interpretations from experimental animal MI models ranging from mice to pigs treated with autologous stem cells reveal consistent benefits in myocardial structure and function despite significant losses of donated cells shortly after adoptive transfer [3436]. However, molecular interventions to enhance survival and persistence of adoptively transferred stem cells improve restoration of myocardial performance and reverse pathologic damage relative to control cells alone [37, 38]. Specifically, genetic modification of CPCs with Pim-1 expression leads to superior cellular regeneration while concurrently increasing cell numbers necessary to improve myocardial structure and function as shown using either murine or human derived CPCs [2, 3]. Telomere length of CPCeP engrafted into damaged myocardium was found to be significantly longer by 2.02- and 2.34-fold relative to CPCe using either murine- [2, 3] or human-derived [2, 3] CPCs, respectively. In addition, CPCeP exhibit a twofold increase in asymmetric chromatid segregation together with enhanced proliferation, thereby increasing the number of committed cells available for myocardial repair [39]. Results presented here are consistent with the premise that myocardial Pim-1 expression prolongs the proliferative phase of CPC growth resulting in a hyperplastic phenotype [22]. The mechanistic basis for beneficial effects of Pim-1 engineering likely rests, in part, with the capacity for proliferation coupled with maintenance of telomere length, both characteristics of youthful myocardial cells. Collectively, antagonism of CPC aging phenotype together with enhanced survival signaling make Pim-1 an attractive molecular interventional approach to enhance CPC-mediated myocardial regeneration.

Precedents in highly mitotic cells support critical roles for c-Myc in acceleration of proliferation. Immortalization of human and mouse fibroblasts occurs with ectopic expression of c-Myc in the presence of activated Ras, however, overexpression of c-Myc alone increases cellular proliferation without transformation [40, 41]. CDC25a, a CDK activating phosphatase and target of c-Myc promotes G1/S transition by targeting and activating cyclin/CDK2 complexes [42, 43]. Interestingly, fibroblasts enter S-phase 2–3 hours faster when cells overexpress CDC25a, demonstrating that CDC25a is sufficient to stimulate DNA synthesis [43]. G1/S transitions are promoted through Pim-1-dependent increases in CDC25a activity and the inhibitory actions of p21 phosphorylation [44]. Pim-1 synergistically co-operates with c-Myc to promote proliferation in neoplastic cell lines and CPCs [22, 45]. Future studies will aim to elucidate the relationship between Pim-1 and CDC25a in CPC mitotic clock regulation.

Dysfunctional telomeres signal cell senescence and cell cycle arrest, however, mitosis can be rescued through reactivation of TERT [46]. Shortened telomeres limit proliferation of cells, slowing the mitotic clock that in time cripples the regenerative capacity of tissues [47]. Senescent CPCs are characterized by short telomeres, increased p53, cell cycle arrest, and heart failure due to the inability of CPCs to replenish apoptotic cardiomyocytes [26, 48]. TERT knockout mice suffer from decreased cardiomyocyte mitosis, increased p53 induced apoptosis, and dilated cardiomyopathy [49] consistent with hearts that have exhausted their CPC reserve. Telomere lengthening due to enhanced TERT activity delays the aging process by allowing more rounds of progenitor cell mitosis and increasing the longevity of the animal [50]. The molecular basis for our results is consistent with the postulate that transient telomere elongation and accelerated cell cycle hinge on the expression of TERT and p53 throughout passaging, as c-Myc and Pim-1 overexpression remain constant in CPCeP (Fig. 4F). Shortly after CPCs are transduced with Pim-1, TERT is upregulated and activated thereby lengthening telomeres. Concurrently Pim-1 drives mitosis and diminishes population doubling time. Acute cell cycle rate increases and telomere lengthening normalizes as TERT activity and expression levels decrease and p53 levels increase. Elevated p53 expression prompted in response to diminished telomere length slows mitosis, thereby inhibiting CPC immortalization. Engineering CPCs ex vivo with Pim-1 to activate TERT and stimulate mitosis is an attractive means of opposing the deleterious effects of aging that is not perpetual and does not lead to cellular immortalization.

Cardiomyopathy in patients treated with doxorubicin is postulated to result from depletion of the CPC population that, in turn, diminishes replacement of damaged myocytes leading to ventricular dilation, wall thinning, and premature mortality [31, 32]. Mechanistically, doxorubicin acts as an oxidative stressor creating DNA damage and promoting apoptosis [51]. Variability in cardiotoxic response to doxorubicin treatment among patients may be a consequence of individual differences in telomere length and TERT activity in the CPCs. Telomere attrition produced by doxorubicin administration is blunted in CPCeP, offering a novel molecular therapeutic intervention for doxorubicin-induced cardiotoxic damage as well as enhancement of regenerative potential for CPC derived from aged or chronically stressed myocardium.

In conclusion, as clinical trials using autologous progenitor cell transplantation advance, the quality of progenitor cells administered is of critical importance. The cellular and molecular phenotypes of the CPCs will determine their efficacy in cardiac repair. Results from this study suggest that Pim-1 promotes a short-lived increase in mitotic rate in conjunction with an acute lengthening of CPC telomeres, characteristics of youthful CPCs. Augmenting the regenerative potential of CPCs through molecular engineering with Pim-1 enhances proliferation and antagonizes the phenotypic characteristics of aging, providing a mechanistic basis for observations of enhanced regeneration using CPCeP in the damaged myocardium.


CONCLUSIONS

  • Increased rate of mitosis in CPCeP.
  • Acute transient telomere lengthening in CPCeP.
  • Pim-1-dependent telomere lengthening requires C-Myc activity in CPCs.
  • Telomeric shortening induced by Dox can be blunted by Pim-1.


We thank all members of the Sussman laboratory for their helpful discussions and technical support. M.A.S. is supported by National Heart, Lung, and Blood Institute Grants R21-HL102714, R01-HL067245, R37-HL091102, P01-HL085577, RC1-HL100891, R21-HL102613, R21 HL104544, and R01 HL105759. C.T.C. is supported by the Rees-Stealy Research Foundation, the San Diego ARCS Foundation, American Heart Association Pre-doctoral Fellowship 10PRE3060046, and an Inamori Foundation Fellowship.

DISCLOSURE OF POTENTIAL CONFLICT OF INTEREST

The authors indicate no potential conflicts of interest.


REFERENCES
1. Bolli R,Chugh AR,D'Amario D,et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trialLancetYear: 20113781847185722088800
2. Fischer KM,Cottage CT,Wu W,et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinaseCirculationYear: 20091202077208719901187
3. Mohsin SKM,Toko H,Bailey B,et al. Human cardiac progenitor cells engineered with Pim-1 kinase enhance myocardial repairJ Am Coll CardiolYear: 2012 July 23, [Epub Ahead of Print].
4. Roger VL,Go AS,Lloyd-Jones DM,et al. Heart disease and stroke statistics—2012 Update: A report from the American Heart AssociationCirculationYear: 2012125e2e22022179539
5. Cesselli D,Beltrami AP,D'Aurizio F,et al. Effects of age and heart failure on human cardiac stem cell functionAm J PatholYear: 201117934936621703415
6. Cherif H,Tarry JL,Ozanne SE,et al. Ageing and telomeres: A study into organ- and gender-specific telomere shorteningNucleic Acids ResYear: 2003311576158312595567
7. de Lange T. Shelterin: The protein complex that shapes and safeguards human telomeresGenes DevYear: 2005192100211016166375
8. Takai H,Smogorzewska A,de Lange T. DNA damage foci at dysfunctional telomeresCurr BiolYear: 2003131549155612956959
9. Oeseburg H,de Boer RA,van Gilst WH,et al. Telomere biology in healthy aging and diseasePflugers ArchYear: 201045925926819756717
10. Palm W,de Lange T. How shelterin protects mammalian telomeresAnnu Rev GenetYear: 20084230133418680434
11. Chen LY,Liu D,Songyang Z. Telomere maintenance through spatial control of telomeric proteinsMol Cell BiolYear: 2007275898590917562870
12. Straatman KR,Louis EJ. Localization of telomeres and telomere-associated proteins in telomerase-negative Saccharomyces cerevisiaeChromosome ResYear: 2007151033105018075778
13. Smogorzewska A,van Steensel B,Bianchi A,et al. Control of human telomere length by TRF1 and TRF2Mol Cell BiolYear: 2000201659166810669743
14. Cerni C. Telomeres, telomerase, and myc. An updateMutat ResYear: 2000462314710648922
15. Feng J,Funk WD,Wang SS,et al. The RNA component of human telomeraseScienceYear: 1995269123612417544491
16. Yamada O,Akiyama M,Kawauchi K,et al. Overexpression of telomerase confers a survival advantage through suppression of TRF1 gene expression while maintaining differentiation characteristics in K562 cellsCell TransplantYear: 20031236537712911124
17. Wong LS,Oeseburg H,de Boer RA,et al. Telomere biology in cardiovascular disease: The TERC−/− mouse as a model for heart failure and ageingCardiovasc ResYear: 20098124425219047341
18. Liu JP,Chen SM,Cong YS,et al. Regulation of telomerase activity by apparently opposing elementsAgeing Res RevYear: 2010924525620362078
19. Cong YS,Wright WE,Shay JW. Human telomerase and its regulationMicrobiol Mol Biol RevYear: 200266407425 table of contents. 12208997
20. Wu KJ,Grandori C,Amacker M,et al. Direct activation of TERT transcription by c-MYCNat GenetYear: 1999212202249988278
21. Zhang Y,Wang Z,Li X,et al. Pim kinase-dependent inhibition of c-Myc degradationOncogeneYear: 2008274809481918438430
22. Cottage CT,Bailey B,Fischer KM,et al. Cardiac progenitor cell cycling stimulated by pim-1 kinaseCirc ResYear: 201010689190120075333
23. Shirogane T,Fukada T,Muller JM,et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosisImmunityYear: 19991170971910626893
24. Bailey B,Izarra A,Alvarez R,et al. Cardiac stem cell genetic engineering using the alphaMHC promoterRegen MedYear: 2009482383319903002
25. Fransioli J,Bailey B,Gude NA,et al. Evolution of the c-kit-positive cell response to pathological challenge in the myocardiumStem CellsYear: 2008261315132418308948
26. D'Amario D,Cabral-Da-Silva MC,Zheng H,et al. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regenerationCirc ResYear: 20111081467148121546606
27. Bianchi A,Shore D. Increased association of telomerase with short telomeres in yeastGenes DevYear: 2007211726173017639079
28. Kang SS,Kwon T,Kwon DY,et al. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunitJ Biol ChemYear: 1999274130851309010224060
29. Chang JT,Lu YC,Chen YJ,et al. hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cellsBr J CancerYear: 20069487087816508638
30. Wang J,Xie LY,Allan S,et al. Myc activates telomeraseGenes DevYear: 199812176917749637678
31. Huang C,Zhang X,Ramil JM,et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult miceCirculationYear: 201012167568320100968
32. De Angelis A,Piegari E,Cappetta D,et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell functionCirculationYear: 201012127629220038740
33. Dohrmann M,Schorr A,Hulsenbeck J,et al. Comparative analysis of stress responses of H9c2 rat cardiomyoblasts following treatment with doxorubicin and tBOOHExp Cell ResYear: 201231877978822265794
34. Li Z,Lee A,Huang M,et al. Imaging survival and function of transplanted cardiac resident stem cellsJ Am Coll CardiolYear: 2009531229124019341866
35. Gyongyosi M,Hemetsberger R,Wolbank S,et al. Imaging the migration of therapeutically delivered cardiac stem cellsJACC Cardiovasc ImagingYear: 2010377277520633856
36. van der Bogt KE,Sheikh AY,Schrepfer S,et al. Comparison of different adult stem cell types for treatment of myocardial ischemiaCirculationYear: 2008118S12112918824743
37. Mangi AA,Noiseux N,Kong D,et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted heartsNat MedYear: 200391195120112910262
38. Dai Y,Xu M,Wang Y,et al. HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemiaJ Mol Cell CardiolYear: 2007421036104417498737
39. Sundararaman B,Avitabile D,Konstandin MH,et al. Asymmetric chromatid segregation in cardiac progenitor cells is enhanced by Pim-1 kinaseCirc ResYear: 20121101169117322441844
40. Amati B,Alevizopoulos K,Vlach J. Myc and the cell cycleFront BiosciYear: 19983d250d2689468463
41. Alevizopoulos K,Vlach J,Hennecke S,et al. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteinsEMBO JYear: 199716532253339311992
42. Hernandez S,Hernandez L,Bea S,et al. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomasCancer ResYear: 199858176217679563496
43. Sexl V,Diehl JA,Sherr CJ,et al. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2OncogeneYear: 1999185735829989807
44. Wang Z,Bhattacharya N,Mixter PF,et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinaseBiochim Biophys ActaYear: 20021593455512431783
45. Forshell LP,Li Y,Forshell TZ,et al. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomasOncotargetYear: 2011244846021646687
46. Jaskelioff M,Muller FL,Paik JH,et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient miceNatureYear: 201046910210621113150
47. Cox LS,Mason PA. Prospects for rejuvenation of aged tissue by telomerase reactivationRejuvenation ResYear: 20101374975421226558
48. Gonzalez A,Rota M,Nurzynska D,et al. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespanCirc ResYear: 200810259760618202313
49. Leri A,Franco S,Zacheo A,et al. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulationEMBO JYear: 20032213113912505991
50. Tomas-Loba A,Flores I,Fernandez-Marcos PJ,et al. Telomerase reverse transcriptase delays aging in cancer-resistant miceCellYear: 200813560962219013273
51. Hoch M,Fischer P,Stapel B,et al. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapiesCell Stem CellYear: 2011913114321816364
Supplementary material

Additional Supporting Information may be found in the online version of this article.

Supplemental Figure 1. Increased population cycling in early passage CPCeP and CPCs isolated from 13 month old hearts and infected with Pim-1, related to Figure 1. A. Cyquant assay performed on CPCe and CPCeP passage 5 (P5) and measured at 4, 6, 24, and 30 hours after plating. B. Cyquant assay performed on isolated older CPCs infected with lentivirus overexpressing GFP (OCPCe) or Pim-1 (OCPCeP). #p=0.09 vs. OCPCe day 3, *p<0.05 vs. OCPCe day 5.

Click here for additional data file (stem0030-2512-SD1.png)

Supplemental Figure 2. Western blots from quantitations in text, related to Figures 2 and 4. A-C. Immunoblots of CPCe and CPCeP at varying passages and probed using antibodies against the indicated proteins. + indicates whole lysates from Hela cells, e is CPCe and eP is CPCeP. ++ Indicates whole cell lysates from CPCs infected with lentivirus overexpressing TERT

Click here for additional data file (stem0030-2512-SD2.png)

Supplement Figure 3. Telomere lengthening in CPCeP is dependent on TERT activity, related to Figure 3. A-D. Early passage CPCs treated with either DMSO or telomerase inhibitor (MST-312, 1μM).

Click here for additional data file (stem0030-2512-SD3.png)

Supplemental Figure 4. Pim-1 interacts with TERT in CPCePs, related to Figure 5. A. Pim-1 and TERT interactions demonstrated by PLA for Pim-1 and TERT (red). B. Coimmunoprecipitation of Pim-1 and TERT. C PLA performed on CPCeP without primary antibodies; this control was performed with every assay to confirm specific staining. D and E. PLAs of Pim-1 and TERT (red), Pim-1 and pS/pT and Tert (red) in CPCeP treated with Pim-1 inhibitor, Quercetagetin (Q, 10μM for 24 hours). F. Pim-1 expression knocked down with a Pim-1 specific siRNA. Lane 1 is CPCeP, lane 2 is CPCe+ siPim- 1, and lane 3 is CPCeP +siPim-1. G and H. PLAs of Pim-1 and TERT (red) and pS/pT and Tert CPCeP treated with siPim-1.

Click here for additional data file (stem0030-2512-SD4.png)

Supplemental Figure 5. TERT expression and DNA incorporation after Dox treatment, related to Figure 7. A. Immunoblots of CPCe and CPCeP treated with Dox and probed for indicated antibodies + indicates whole cell Hela lysates. B. DNA synthesis measured by BrdU incorporation in DOX treated and untreated CPCs. $ p<0.05 vs untreated CPCe.

Click here for additional data file (stem0030-2512-SD5.png)


Figures

[Figure ID: fig01]
Figure 1 

Temporary increases in proliferation and reduced CPC doubling time with Pim-1 overexpression. (A): CPC proliferation determined by CyQUANT assay. *, p < .05 versus CPCe at same passage. (B, C): Calculated CPC doubling time determined by CyQUANT and Trypan blue cell counts. **, p < .01 versus CPCe, #, p < .05 versus OCPCe. CPCe, CPCeP, CPCs isolated from 13-month old FVB mice overexpressing eGFP, Pim-1, CPCePDN, and CPCTERT. CPC doubling times in (C) are calculated three passages after transduction with indicated lentivirus. Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1; OCPCe, old CPCs overexpressing eGFP; OCPCeP, old CPCs overexpressing Pim-1; CPCPDN, CPCs overexpressing a kinase dead mutant of Pim-1; CPCTERT, CPCs overexpressing TERT.



[Figure ID: fig02]
Figure 2 

Telomerase activation and telomere lengthening in CPCs from aged hearts. (A, B): CPCs isolated from 13-month old mouse hearts and infected with eGFP or Pim-1 (OCPCe or OCPCeP, respectively) were plated and subjected to quantitative fluorescent in situ hybridization to determine telomere length (dashed red lines indicate averages). (C): Telomere lengths of CPCs isolated from 2-month-old FVB hearts demonstrate telomere lengths in younger CPCs. (D):TERT gene determined by reverse transcription polymerase chain reaction. (E): TERT expression levels in OCPCe and OCPCeP three passages after infection. (F): TERT activity measured by TRAP assay. Dashed red lines represent average telomere lengths. Results are mean ± SEM. *, p, < .05 versus OCPCe; **, p < .01 versus OCPCe, telomere lengths between OCPCe and OCPCeP are significantly different p < .001 measured by KS test. Abbreviations: CPC, cardiac progenitor cell; OCPCe, old CPCs overexpressing eGFP; OCPCeP, old CPCs overexpressing Pim-1.



[Figure ID: fig03]
Figure 3 

Telomere length is increased in CPCeP. (A, B): Telomere lengths in early passages (4–6) CPCe and CPCeP measured by quantitative fluorescent in situ hybridization (**, p < .01). (C, D): Telomere lengths in later passages (11–13) of CPCe and CPCeP, telomere lengths are no longer statistically different. (E): Telomere length is significantly decreased in early passage CPCePDN (**, p < .01 vs. CPCe by KS test). Dashed red lines represent average telomere lengths. (F): CPCe and CPCeP telomeres visualized by QFISH (white foci), nuclei are stained using To-Pro-3 (blue). Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1; CPCePDN, CPCs overexpressing a kinase dead mutant of Pim-1.



[Figure ID: fig04]
Figure 4 

Telomere lengthening in CPCeP is due to acute increases TERT activity. (A): Average telomere lengths in CPCe and CPCeP throughout 22 passages, **, p < .001 versus CPCe passages 4–6. (B): TERT protein expression at varying passages, values are fold change divided by low passage CPCe (4–6). (C): Telomerase activity of CPCe and CPCeP from various passages post-transduction. (D): Telomerase activity in low passage CPCePDN (p 4–6) and after short hairpin deletion of Pim-1 in CPCe and CPCeP. (E): p53 protein expression at multiple passages determined by immunoblot and standardized to GAPDH expression. (F): Summary of mechanism for transient telomere lengthening and increased mitotic rate in CPCeP. **, p < .01; *, p < .05 all statistics determined by KS test, Student's t test, or two-way ANOVA where applicable. Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1; CPCe-PDN, CPCs overexpressing a kinase dead mutant of Pim-1; shPim, short hairpin deletion of Pim-1.



[Figure ID: fig05]
Figure 5 

TERT phosphorylation declines over passaging in CPCeP. (A–D): Phosphorylated TERT on threonine residues and serine residues (E–H, red), cell body is visualized using GFP (green), and nuclei are stained with Sytox (white). Early passage CPCeP (4) demonstrates increased pThr/TERT and pSer/TERT that diminishes over passaging (CPCeP passage 11). Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1; CPCePDN, CPCs overexpressing a kinase dead mutant of Pim-1; GFP, green fluorescent protein.



[Figure ID: fig06]
Figure 6 

Myc inhibition blocks Pim-1 mediated telomere elongation. (A): Expression of c-Myc by immunoblot, GAPDH is used as a loading control. (B): Reverse transcription polymerase chain reaction of c-Myc target genes TERT and eLF4 (control) in vehicle (DMSO) CPCeP or CPCe and CPCeP +MycI (50 μM for three passages) values are fold change over vehicle treated CPCe. (C): TERT activity in vehicle and MycI CPCe and CPCeP (*, p < .01 vs. CPCe vehicle treated; **, p < .01 vs. CPCeP vehicle treated; $, p < .05 CPCe vehicle vs. CPCe MycI treated). (D, E): Telomere lengths of vehicle-treated CPCe and CPCeP and (F, G) Myc I treated, telomere length determined by quantitative fluorescent in situ hybridization (**, p < .0001 vs. vehicle CPCe; #, p = .002 vs. MycI CPCe, and $, p < .0001 vs. CPCeP vehicle determined by KS test). Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1.



[Figure ID: fig07]
Figure 7 

Telomere length is preserved in CPCePs challenged with Doxorubicin. (A): Fold change increase in TERT protein in CPCeP after Dox treatment (passages 13–15, 4 hours 1 μM Dox). (B): TERT activity in CPCs 4 hours after Dox measured by TRAP, values are fold change over Dox treated CPCe (*, p < .05). (C): Caspase eight activity was determined after Dox treatment; values are fold change over untreated CPCe. (D–G): QFISH analysis in untreated and Dox treated CPCe and CPCeP at the same passages. (H, I): Telomere length measurements in CPCe and CPCeP treated with Dox and MycI. (*, p < .01 vs. untreated CPCe; **, p < .001 vs. untreated CPCe). Abbreviations: CPC, cardiac progenitor cell; CPCe, CPCs overexpressing eGFP; CPCeP, CPCs overexpressing Pim-1; Dox, Doxorubicin.



Article Categories:
  • Tissue-Specific Stem Cells

Keywords: Pim-1, Telomere, Cardiac progenitor cell, Telomerase.

Previous Document:  Enhanced phytase production from Achromobacter sp. PB-01 using wheat bran as substrate: Prospective ...
Next Document:  In vivo corrosion mechanism by elemental interdiffusion of biodegradable Mg-Ca alloy.